人参皂苷Rg3联合紫杉醇协同抗胃癌细胞增殖的研究

Experiment Study of Gisenoside Rg3 and Paclitaxel on inhibiting Gastric cancer Cells' Proliferation

目的:探讨人参皂苷Rg3联合紫杉醇是否具有协同抗胃癌细胞增殖的作用。方法:将人胃癌BGC—823细胞裸鼠移植瘤动物模型,随机分为4组(每组10只):人参皂苷Rg3组[GS-Rg3:10mg/(kg.d)灌胃],紫杉醇组(紫杉醇10mg/kg腹腔内注入,每周2次),联合组(人参皂苷Rg3+紫杉醇,用法同上),对照组(生理盐水组)。连续用药3周。用药结束后脱颈处死裸鼠,统计各组抑瘤率;免疫组化检测增殖细胞核抗原(PCNA)。结果:联合组(人参皂苷Rg3+紫杉醇)抑瘤率明显大于人参皂苷Rg3组和紫杉醇组(P<0.01);联合组增殖细胞核抗原(PCNA)活性最低,与人参皂苷Rg3组、紫杉醇组比较有显著差异(P<0.01和P<0.05)。结论:人参皂苷Rg3联合紫杉醇能协同抗胃癌细胞增殖,抑制肿瘤的生长。

Objective： To study whether Ginsenoside Rg3 combined with Paclitaxel could inhibit gastric cancer Cells＇ Pro- liferation. Methods ： Transplantation tmnor models of gastric cancer eellsBGC - 823 in SCID mice were randomly divided into four groups（ 10 mice per group） ： Ginsenoside Rg3 group[ GS -Rg3： 10mg/（ kg·d） intragastrie administration, for three weeks], Paclitaxel group（ Paclitaxel at 10mg/Kg was injected into abdominal cavity two times per week, for three weeks） , the combined group （GS - Rg^3 ＋ Paclitaxel, using the same method above）. After medication was over, every group of mice were decapitated, cancer inhibition rates were tested, immunohistochemistry was to detect proliferating cell nuclear antigen（PCNA）. Results： Cancer inhibition rate of the combined group （GS -Rg^3 ＋ Paclitaxel） was significantly larger than GS- Rg^3 group and Paclitaxel group（ P 〈 0.01 ） ;the PCNA activity of the combined group was the lowest and there was significant difference contrast to GS - Rg3 or Paclitaxel group （P 〈 0.01, P 〈 0. 05 ）. Conclusion： GS - Rg3 combined with Paclitaxel could inhibit gastric cancer Cells＇ Proliferation , inhibit tumors＇ growth.